These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 4076201)

  • 1. Single-chain urokinase-type plasminogen activators: new hopes for clot-specific lysis.
    Flohé L
    Eur Heart J; 1985 Nov; 6(11):905-8. PubMed ID: 4076201
    [No Abstract]   [Full Text] [Related]  

  • 2. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W; Vanhaecke J; Stump DC; Van de Werf F; Holmes W; Guenzler WA; Flohe L; Collen D
    J Am Coll Cardiol; 1986 Jul; 8(1):118-24. PubMed ID: 3086416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intrinsic lysis concept.
    Gurewich V; Liu JN; Pannell R
    Ann N Y Acad Sci; 1992 Dec; 667():224-32. PubMed ID: 1309040
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue-type plasminogen activator (t-PA): an agent with promise for selective thrombolysis.
    Tiefenbrunn AJ; Sobel BE
    Int J Cardiol; 1985 Jan; 7(1):82-6. PubMed ID: 3932227
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of lipoprotein(a) on thrombolysis.
    von Hodenberg E; Pestel E; Kreuzer J; Freitag M; Bode C
    Chem Phys Lipids; 1994 Jan; 67-68():381-5. PubMed ID: 8187238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis.
    Marder VJ; Francis CW
    Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729
    [No Abstract]   [Full Text] [Related]  

  • 8. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolysis with tissue-type plasminogen activator in acute myocardial infarction. Potentials and pitfalls.
    Jaffe AS; Sobel BE
    JAMA; 1986 Jan; 255(2):237-9. PubMed ID: 3079842
    [No Abstract]   [Full Text] [Related]  

  • 10. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer thrombolytic drugs for acute myocardial infarction.
    Reddy DS
    Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial experiences with pro-urokinase in acute myocardial infarct].
    Schanzenbächer P; Huber J; Keller F; Kochsiek K
    Z Kardiol; 1987 Sep; 76(9):570-5. PubMed ID: 3122430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis during acute myocardial infarction.
    Lew AS; Ganz W
    Acute Care; 1985; 11(1):3-39. PubMed ID: 2940795
    [No Abstract]   [Full Text] [Related]  

  • 17. Coronary thrombolysis with tissue-type plasminogen activator: an overview.
    Van de Werf F; Collen D
    Eur Heart J; 1985 Nov; 6(11):902-4. PubMed ID: 3935445
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.